scholarly journals Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment

2013 ◽  
Vol 6 (3) ◽  
pp. 821-828 ◽  
Author(s):  
YAO LIU ◽  
LI JIANG ◽  
YI MU
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B ◽  
Somatostatin Receptor ◽  
Receptor Subtypes ◽  
Somatostatin Receptor Subtypes ◽  
Long Acting

scholarly journals Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors

2014 ◽  
Vol 22 (1) ◽  
pp. 1-9 ◽  
Author(s):  
M Cives ◽  
P L Kunz ◽  
B Morse ◽  
D Coppola ◽  
M J Schell ◽  
...  
Keyword(s):  
Phase Ii ◽  
Somatostatin Receptor ◽  
Favorable Effect ◽  
Clinical Activity ◽  
Receptor Subtypes ◽  
Open Label ◽  
Radiographic Response ◽  
Somatostatin Receptor Subtypes ◽  
Grade 3 ◽  
Long Acting

Pasireotide long-acting repeatable (LAR) is a novel somatostatin analog (SSA) with avid binding affinity to somatostatin receptor subtypes 1, 2, 3 (SSTR1,2,3) and 5 (SSTR5). Results from preclinical studies indicate that pasireotide can inhibit neuroendocrine tumor (NET) growth more robustly than octreotidein vitro. This open-label, phase II study assessed the clinical activity of pasireotide in treatment-naïve patients with metastatic grade 1 or 2 NETs. Patients with metastatic pancreatic and extra-pancreatic NETs were treated with pasireotide LAR (60 mg every 4 weeks). Previous systemic therapy, including octreotide and lanreotide, was not permitted. Tumor assessments were performed every 3 months using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS), overall radiographic response rate (ORR), and safety. Twenty-nine patients were treated with pasireotide LAR (60 mg every 4 weeks) and 28 were evaluable for response. The median PFS was 11 months. The most favorable effect was observed in patients with low hepatic tumor burden, normal baseline chromogranin A, and high tumoral SSTR5expression. Median OS has not been reached; the 30-month OS rate was 70%. The best radiographic response was partial response in one patient (4%), stable disease in 17 patients (60%), and progressive disease in ten patients (36%). Although grade 3/4 toxicities were rare, pasireotide LAR treatment was associated with a 79% rate of hyperglycemia including 14% grade 3 hyperglycemia. Although pasireotide appears to be an effective antiproliferative agent in the treatment of advanced NETs, the high incidence of hyperglycemia raises concerns regarding its suitability as a first-line systemic agent in unselected patients. SSTR5expression is a potentially predictive biomarker for response.

scholarly journals 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5

2004 ◽  
Vol 32 (6) ◽  
pp. 724-724 ◽  
Author(s):  
Damian Wild ◽  
Helmut R. Mäcke ◽  
Beatrice Waser ◽  
Jean Claude Reubi ◽  
Mihaela Ginj ◽  
...  
Keyword(s):  
Pet Imaging ◽  
Somatostatin Receptor ◽  
Receptor Subtypes ◽  
High Affinity ◽  
Somatostatin Receptor Subtypes

Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors

Pancreas ◽  
2016 ◽  
Vol 45 (2) ◽  
pp. 187-192 ◽  
Author(s):  
Ki Byung Song ◽  
Song Cheol Kim ◽  
Ji Hun Kim ◽  
Dong-Wan Seo ◽  
Seung-Mo Hong ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Prognostic Value ◽  
Somatostatin Receptor ◽  
Receptor Subtypes ◽  
Pancreatic Neuroendocrine Tumors ◽  
Somatostatin Receptor Subtypes

scholarly journals Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Wenjuan Liu ◽  
Lina Xie ◽  
Min He ◽  
Ming Shen ◽  
Jingjing Zhu ◽  
...  
Keyword(s):  
Tumor Size ◽  
Tumor Volume ◽  
Somatostatin Receptor ◽  
Somatostatin Analogues ◽  
Receptor Subtypes ◽  
Short Term ◽  
Pituitary Growth Hormone ◽  
Term Efficacy ◽  
Somatostatin Receptor Subtypes ◽  
Pretreated Group

The expression of somatostatin receptor subtypes (SSTRs) in pituitary growth hormone- (GH-) secreting adenomas may predict the response to somatostatin analogues (SSA). Our aim was to evaluate the value of the immunohistochemical (IHC) scores of 2 subtypes, SSTR2 and SSTR5, in predicting the short-term efficacy of SSA therapy in patients with active acromegaly. Ninety-three newly diagnosed acromegalic patients were included in our study. These patients were categorized into either a SSA-pretreated group (SA, n=63) or a direct-surgery group (DS, n=30), depending on whether or not presurgical SSA treatment was received. IHC analysis, using a 12-grade scoring system, with rabbit monoclonal antibodies against SSTR2 and SSTR5, was performed on all adenoma tissues. The reduction of GH, IGF-1, and tumor size after treatment with SSA for 3 months was measured. Compared with that in the DS group, SSTR2 expression was lower in the SA group. Additionally, in the SA group, SSTR2 expression was positively correlated with the reduction of IGF-1 and tumor volume. However, there was no correlation between the SSTR5 score and the efficacy of SSA. In conclusion, the protein expression of SSTR2, but not of SSTR5, is a valuable indicator in predicting biochemical and tumor size response to short-term SSA treatment in acromegalic patients.

Differentiated expression of somatostatin receptor subtypes in experimental models and clinical neuroblastoma

2010 ◽  
Vol 56 (4) ◽  
pp. 584-589 ◽  
Author(s):  
Kleopatra Georgantzi ◽  
Apostolos V. Tsolakis ◽  
Mats Stridsberg ◽  
Åke Jakobson ◽  
Rolf Christofferson ◽  
...  
Keyword(s):  
Somatostatin Receptor ◽  
Experimental Models ◽  
Receptor Subtypes ◽  
Somatostatin Receptor Subtypes

Role of Somatostatin Receptor Subtypes in Acromegaly

2005 ◽  
Vol 15 (6) ◽  
pp. 377-383 ◽  
Author(s):  
Joost van Der Hoek ◽  
Steven W. J. Lamberts ◽  
Leo J. Hofland
Keyword(s):  
Somatostatin Receptor ◽  
Receptor Subtypes ◽  
Somatostatin Receptor Subtypes
Sign in / Sign up

Export Citation Format

Share Document